Flixonase Safety in Patients With Allergic Rhinitis (AR)

GlaxoSmithKline1 enrolled

Overview

This is an inception cohort study that analyses data from an administrative medical records database. The two inception cohorts are: 1) patients initiated on intranasal FP and 2) patients initiated on another INS (not FP). The candidates for the inception cohorts did not use any intranasal steroid in the year prior to initiation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rhinitis, Allergic, Perennial

Interventions

Intermittent, sub-chronic and chronic Flixonase useDRUG

Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.

Intermittent, sub-chronic and chronic use of intranasal steroids other than FlixonaseDRUG

Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.

Eligibility

Sex: ALLMin age: 4 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient records dated between January 1990 - January 2002 were used to develop the overall study cohort. The cohort was composed of the following patients: 1. All patients with at least one prescription for Flixonase 2. A random sample of patients having at least one prescription for an INS other than Flixonase Exclusion Criteria: Patient-level exclusion * Patients with less than 180 days of continuous eligibility before index date * Patients who are under four years of age at index date * Patients who are older than 85 years of age at index date Episode-level exclusion -When patient history was divided into Flixonase or other INS use episodes, patients with less than 120 days of eligibility after the last prescription in the episode Patients with an event of interest 180 days prior to patients' entry into the cohort or anytime prior to an episode index date were automatically excluded from the analysis of that event. This exclusion criterion was applied to rule out prevalent conditions.

Outcomes

Primary Outcomes

Steroid-related outcomes: Cataracts, Glaucoma, Nasal septum perforation, Hypercorticism, Adrenal insufficiency, Fractures (limited to hip, wrist and vertebral as proxies for osteoporosis), Otitis media, Sinusitis, Infectious complications of sinusitis

Time frame: Exposure episodes are defined as any series of prescriptions filled within 60 days of one another. Observation periods capture incident events beginning with the first prescription in the episode and ending 120 days after the last fill date.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.